Rethinking Safety Perceptions Around JAK Inhibitors in Vitiligo

In "Rethinking Safety Perceptions Around JAK Inhibitors in Vitiligo," Dr. Desai confronts the safety perceptions that still shadow JAK inhibitor use in vitiligo.

Dr. Desai frames safety as paramount, noting that an underlying comorbidity should not automatically disqualify a patient from systemic treatment, since these therapies may simultaneously benefit other autoimmune or metabolic conditions linked to vitiligo. He describes how JAK inhibitor safety monitoring has transformed over the past five years, with far more refined lab screening and follow-up intervals than earlier protocols required. Three to five years of safety data in other diseases, including atopic dermatitis, show no meaningful signal for major adverse cardiovascular events or venous thromboembolism, reassuring him as both a treating physician and clinical investigator across these trial programs.

He is direct about where caution remains warranted: a history of multiple blood clots would make him avoid an oral JAK inhibitor, while conditions like hyperlipidemia, uncontrolled hypertension, diabetes, or metabolic syndrome call for coordinated care with a patient's primary physician rather than automatic disqualification. He emphasizes documenting risk discussions with every patient regardless of comorbidity status.

Dr. Desai pushes back specifically on how black box warnings get applied to vitiligo populations. The original warning, he explains, stemmed from rheumatoid arthritis patients over age fifty who had already failed multiple prior therapies, a fundamentally different risk profile than most vitiligo patients being considered for treatment. He argues this is not an apples-to-apples comparison and warns against inappropriately frightening patients away from appropriate care. He points out, somewhat pointedly, that ibuprofen's package insert carries more black box warnings than JAK inhibitors do, and that acetaminophen carries real liver failure risk, arguing that risk communication should stay proportionate and grounded rather than reflexively alarmist as more long-term data accumulates.

Up next, in "Weighing Topical and Systemic Therapy as Vitiligo Options Expand," Jason and Dr. Lal weigh localized versus systemic therapy as more options reach the market.